Table 5 The HR of etiology in the studies
Authors (year) | Study design | Aetiology | Endpoint | HR |
|---|---|---|---|---|
Kudo et al. (2011) [15] | RCT trial | HBV = 20% | TTP | 0.81(0.62–1.07) |
|  |  | HCV = 60% |  |  |
Bai et al. (2013) [46] | Comparative study | HBV = 87.9% | OS | 1.01(0.60–1.71) |
|  |  | HCV = 4.9% |  |  |
Muhammad et al. (2013) [47] | Comparative study | ST:HCV = 69% | OS | 1.04(0.66–1.63) |
|  |  | DT:HCV = 93% |  |  |
Zhao et al. (2013) [41] | Non-comparative study | HBV = 80% | OS | 1.372(0.773–2.437) |
|  |  | HCV = 5% |  |  |
Hu et al. (2014) [14] | Comparative study | ST:B = 82.9% | TTP | 1.01(0.76–1.34) |
|  |  | T:B = 79.8% |  |  |
Yao et al. (2016) [12] | Comparative study | ST:HBV = 84% | OS | 1.228(0.593–2.540) |
|  |  | T:HBV = 83% | TTP | 0.878(0.494–1.561) |